1521O A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with highly life-threatening unmet medical needs (NCCH1806/MK004)
| Autor: | Kojima, Y., Shimizu, T., Yonemori, K., Koyama, T., Matsui, N., Kamikura, M., Tomatsuri, S., Okuma, H.S., Shimoi, T., Noguchi, E., Sudo, K., Hirakawa, A., Sadachi, R., Okita, N.T., Nakamura, K., Yamamoto, N., Fujiwara, Y. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S1111-S1112 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|